newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway